Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV): Which Company Needs a HCV Win?

AbbVie Inc (NYSE:ABBV) spun off from Abbott earlier this year and was born carrying over a dozen of the mother ship’s research-based pharmaceuticals. Based on the 2012 sales of those products, Humira now accounts for over 50% of AbbVie Inc (NYSE:ABBV)’s overall net sales. Niaspan and Tricor added up to over 10% of net sales and both of those drugs will fall off patent this year.

It seems likely that AbbVie will receive an HCV approval and go toe-to-toe with Gilead Sciences, Inc. (NASDAQ:GILD). But take away the HCV drug plus the attempts at broadening Humira’s approved indications and the AbbVie pipeline looks very stark. A strong showing with the HCV drugs could help offset concerns about the company’s small number of development projects.

Foolish final thoughts

Merck & Co., Inc. (NYSE:MRK)’s interferon sales could still help the company stay afloat as it charts a new course without the patent-expired Singulair. But you should mostly count Merck & Co., Inc. (NYSE:MRK) out of the HCV game.

Gilead’s HCV victory is widely expected so a stumble would sting. But AbbVie desperately needs some more backup for Humira — and to show that it’s capable of churning out another blockbuster.

The article Which Company Needs a HCV Win? originally appeared on Fool.com and is written by Brandy Betz.

Brandy Betz has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences (NASDAQ:GILD). Brandy is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.